Market cap
$13 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
0
P/B Ratio
1.2
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | -- | -- | -- | -- | -- |
| EBIT | 41.11 | 0.98 | -13.96 | -1.13 | -13.46 |
| Net Profit | 40.56 | 0.07 | -14.23 | -1.22 | -156.94 |
| EPS | 56.84 | 89.07 | 85.51 | 25.07 | 14.31 |
| Book Value | -- | -- | -89.39 | -81.00 | -61.85 |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Dec-25 | Dec-24 |
| EBIT-Margin
| -- | -- | -- | -- | -- |
| Net Margin
| -- | -- | -- | -- | -- |
| Return on equity
| -177.24 | -121.76 | -228.08 | -319.85 | -135.80 |
| Return on Capital
| -171.38 | -118.17 | -- | -307.58 | -131.48 |
| Return on Assets
| -104.36 | -76.43 | -102.26 | -171.88 | -78.93 |
| Debt to Equity (x)
| -- | -- | 0.00 | 0.02 | 0.08 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Moleculin Biotech (MBRX)
|
--
|
-307.58
|
-131.48
|
-75.09
|
-44.05
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
-228.08
Lower than Peers by 247.05
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Moleculin Biotech (MBRX)
|
-228.08
|
-319.85
|
-135.80
|
-76.07
|
-44.25
|
|
Peer Median
|
18.97
|
--
|
--
|
--
|
--
|
ROA
-102.26
Lower than Peers by 105.11
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Moleculin Biotech (MBRX)
|
-102.26
|
-171.88
|
-78.93
|
-62.25
|
-41.02
|
|
Peer Median
|
2.86
|
--
|
--
|
--
|
--
|
EBIT Margin
--
--
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Moleculin Biotech (MBRX)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
15.82
|
--
|
--
|
--
|
--
|
Net Margin
--
--
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Moleculin Biotech (MBRX)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
8.23
|
--
|
--
|
--
|
--
|
Revenue Growth
--
--
Year on year growth in net sales
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Moleculin Biotech (MBRX)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
8.05
|
--
|
--
|
--
|
--
|
EBIT Growth
-13.96
Lower than Peers by 22.23
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Moleculin Biotech (MBRX)
|
-13.96
|
-54.21
|
26.89
|
-2.56
|
-82.62
|
|
Peer Median
|
8.26
|
--
|
--
|
--
|
--
|
Net Profit Growth
-14.23
Lower than Peers by 21.96
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Moleculin Biotech (MBRX)
|
-14.23
|
-54.21
|
26.89
|
-2.56
|
-82.62
|
|
Peer Median
|
7.73
|
--
|
--
|
--
|
--
|
EPS Growth
85.51
Higher than Peers by 75.12
Year on year growth in earnings per share
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Moleculin Biotech (MBRX)
|
85.51
|
0.93
|
0.57
|
0.02
|
-0.82
|
|
Peer Median
|
10.39
|
--
|
--
|
--
|
--
|
Book Value Growth
117.68
Higher than Peers by 112.81
Year on year growth in book value per share
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Moleculin Biotech (MBRX)
|
117.68
|
--
|
--
|
--
|
--
|
|
Peer Median
|
4.87
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
--
--
Total debt / Net worth
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Moleculin Biotech (MBRX)
|
--
|
0.02
|
0.08
|
0.02
|
0.01
|
|
Peer Median
|
0.59
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
0.01
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Moleculin Biotech (MBRX)
|
0.01
|
0.01
|
0.02
|
0.00
|
0.00
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
0.94
Lower than Peers by 0.71
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Moleculin Biotech (MBRX)
|
0.94
|
1.41
|
0.97
|
3.86
|
9.46
|
|
Peer Median
|
1.65
|
--
|
--
|
--
|
--
|
Quick Ratio
0.94
Lower than Peers by 0.26
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Moleculin Biotech (MBRX)
|
0.94
|
--
|
--
|
3.86
|
9.47
|
|
Peer Median
|
1.20
|
--
|
--
|
--
|
--
|
Interest Coverage
-387.81
Lower than Peers by 392.58
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Moleculin Biotech (MBRX)
|
-387.81
|
--
|
--
|
--
|
-17.97
|
|
Peer Median
|
4.77
|
--
|
--
|
--
|
--
|
Operating Efficiency
Asset Turnover
--
--
Sales / Average Total Assets
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Moleculin Biotech (MBRX)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
0.40
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Moleculin Biotech (MBRX)
|
--
|
--
|
0.00
|
-31.63
|
-55.12
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Moleculin Biotech (MBRX)
|
--
|
11,237.53
|
6,562.90
|
6,604.70
|
2,845.49
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
0.04
Lower than Peers by 37.27
Current share price divided by earning per share in the last twelve months
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Moleculin Biotech (MBRX)
|
0.04
|
-0.32
|
-0.01
|
0.00
|
0.00
|
|
Peer Median
|
37.32
|
--
|
--
|
--
|
--
|
Price / Book Value
1.17
Lower than Peers by 6.59
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Moleculin Biotech (MBRX)
|
1.17
|
0.71
|
0.04
|
0.00
|
0.00
|
|
Peer Median
|
7.75
|
--
|
--
|
--
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Moleculin Biotech (MBRX)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
0.50
|
--
|
--
|
--
|
--
|
EV/EBITDA
0.52
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Moleculin Biotech (MBRX)
|
0.52
|
-0.06
|
0.17
|
0.77
|
1.47
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Market Cap
13
Lower than Peers by 2,508
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Moleculin Biotech (MBRX)
|
13
|
--
|
--
|
--
|
--
|
|
Peer Median
|
2,521
|
--
|
--
|
--
|
--
|